SCHG vs XBI
Schwab US Large-Cap Growth ETF vs SPDR S&P Biotech ETF
- • SCHG has the lower expense ratio at 0.04% vs 0.35% for XBI.
- • SCHG pays a higher dividend yield (0.40%).
Side-by-side metrics
| Metric | SCHG | XBI |
|---|---|---|
Expense ratio Annual fee. Lower is better. | 0.04% | 0.35% |
Dividend yield Trailing 12-month yield. | 0.40% | 0.35% |
AUM Assets under management — bigger funds are typically more liquid. | $61.69B | $10.92B |
YTD return | 4.82% | 28.80% |
1-year return | — | — |
3-year return Annualized. | — | — |
5-year return Annualized. | — | — |
10-year return Annualized. | — | — |
Beta (3Y) Volatility relative to the market. Closer to 1 = market-like. | 1.19 | 1.01 |
P/E ratio | 27.01 | — |
Last price | $34.60 | $156.41 |
Inception | — | — |
Issuer | Schwab | State Street |
SCHG top holdings
| AAPL | Apple Inc | 12.07% |
| NVDA | NVIDIA Corp | 11.88% |
| MSFT | Microsoft Corp | 9.30% |
| AMZN | Amazon.com Inc | 5.66% |
| AVGO | Broadcom Inc | 4.07% |
| GOOGL | Alphabet Inc Class A | 3.94% |
| META | Meta Platforms Inc Class A | 3.77% |
| GOOG | Alphabet Inc Class C | 3.17% |
| LLY | Eli Lilly and Co | 3.16% |
| TSLA | Tesla Inc | 3.14% |
XBI top holdings
| MRNA | Moderna Inc | 2.37% |
| NTRA | Natera Inc | 1.82% |
| HALO | Halozyme Therapeutics Inc | 1.77% |
| TWST | Twist Bioscience Corp | 1.77% |
| BIIB | Biogen Inc | 1.75% |
| AMGN | Amgen Inc | 1.73% |
| EXEL | Exelixis Inc | 1.73% |
| UTHR | United Therapeutics Corp | 1.72% |
| ABBV | AbbVie Inc | 1.71% |
| GILD | Gilead Sciences Inc | 1.70% |
About SCHG
SCHG (Schwab US Large-Cap Growth ETF) is Large-cap US growth at low cost. Managed by Schwab, the fund carries $61.7B in assets under management, an expense ratio of 0.04%, a dividend yield of 0.40%. Its largest holding is Apple Inc (AAPL), which represents 12.1% of the portfolio. Real Estate is the fund's largest sector exposure at 0.3%.
About XBI
XBI (SPDR S&P Biotech ETF) is Equal-weight biotech stocks in the S&P Biotech Index. Managed by State Street, the fund carries $10.9B in assets under management, an expense ratio of 0.35%, a dividend yield of 0.35%. Its largest holding is Moderna Inc (MRNA), which represents 2.4% of the portfolio. Financial Services is the fund's largest sector exposure at 0.6%.